Article Text

Download PDFPDF
Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis
  1. Marine Godfroy1,
  2. Cécile Loaec1,
  3. Dominique Berton2,
  4. Catherine Guérin-Charbonnel3,4 and
  5. Jean-Marc Classe1
  1. 1 Chirurgical oncologie Department. ICO Cancer Center, René Gauducheau Centre, Saint Herblain, France
  2. 2 Medical oncology Department, ICO Cancer Center, René Gauducheau Centre, Saint Herblain, France
  3. 3 Clinical Research Department, ICO Cancer Center, Saint Herblain, France
  4. 4 Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France
  1. Correspondence to Dr Marine Godfroy, Gynécologie, CHU Angers, Nantes, France; marinegodfroy{at}orange.fr; Dr Cécile Loaec, Institut Cancérologique de l'Ouest, Saint Herblain, France; Cecile.Loaec{at}ico.unicancer.fr; Dr Dominique Berton, Medical oncology Department, ICO Cancer Center, René Gauducheau Centre, Saint Herblain, France; dominique.berton{at}ico.unicancer.fr; Mrs Catherine Guérin-Charbonnel; Catherine.Guerin{at}ico.unicancer.fr; Professor Jean-Marc Classe; Jean-Marc.Classe{at}ico.unicancer.fr

Abstract

Objectives This retrospective study aimed to assess the efficiency of consolidation chemotherapy after 6 cycles of neoadjuvant chemotherapy and delayed complete surgery on overall survival and progression-free survival among patients with advanced epithelial ovarian cancer.

Methods This was a retrospective consecutive study with a propensity score to ensure balance for the baseline characteristics between the study groups. All patients treated for advanced ovarian cancer with 6 cycles of neoadjuvant chemotherapy followed by delayed complete surgery, without post-operative chemotherapy (group 1), or with post-operative chemotherapy (group 2), were included. We evaluated survival and the quality of cytoreductive surgery using the propensity score.

Results From 2000 to 2017, 42 patients were included in group 1, and 59 in group 2. The median follow-up was 78 months (confidence interval (CI) 95% (60.1; not computable)). Neither progression-free survival nor overall survival were different between the two groups. The median progression-free survival was 10.2 months (CI 95% (8.8–17.0)) for group 1 and 10.4 months (CI 95% (7.9–12.8)) for group 2 (p=0.57). Five-year overall survival was 21.0% (CI 95% (10.4–42.3)) for group 1 and 26.1% (CI 95% (16.0–42.5)) for group 2 (p=0.73).

Conclusions Adding cycles of consolidation chemotherapy after delayed surgery following 6 cycles of neoadjuvant chemotherapy did not demonstrate any survival improvement in patients treated for advanced ovarian cancer not amenable to primary or interval surgery.

  • Ovarian Neoplasms
  • Surgical Oncology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @Godfroy

  • Contributors MG: conceptualization, validation, resources, writing original draft, writing, review, editing. CL: conceptualization, validation, writing, review, editing, supervision. DB: validation. CG-C: data curation and analysis, writing, review, editing. J-MC: conceptualization, validation, writing, review, editing, supervision, project administration,

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.